From ESC 2024: Common Pitfalls to Avoid When Interpreting Clinical Trials, with Deepak Bhatt, MD, MPH, MBA
From ESC 2024: Common Pitfalls to Avoid When Interpreting Clinical Trials, with Deepak Bhatt, MD, MPH, MBA Although clinical trial data can prove invaluable and have practice-altering implications, the timeline from data release to adoption into clinical practice can sometimes take years. According to a study conducted in 2011, it takes approximately 17 for scientific […]
Newly reported from ESC 2024: Endometriosis Linked to Elevated Risk of Heart Attack, Stroke in Women
Newly reported from ESC 2024: Endometriosis Linked to Elevated Risk of Heart Attack, Stroke in Women Women with endometriosis have an approximately 20% greater risk of significant cardiac outcomes, including acute myocardial infarction and ischemic stroke, compared with women without endometriosis, according to new data presented at the European Society of Cardiology (ESC) Congress 2024. The study […]
Reporting from ESC 2024: Catching Up on Sleep on Weekends Links to 20% Lower Risk of Developing Heart Disease
Reporting from ESC 2024: Catching Up on Sleep on Weekends Links to 20% Lower Risk of Developing Heart Disease A recent study revealed people who had the most catch-up sleep on the weekends had a 20% lower risk of developing heart disease compared with those with the least weekend catch-up sleep. “The association becomes even more pronounced among individuals […]
News Coverage from ESC 2024: Vutrisiran Reduces Cardiovascular Risk, Improves Quality of Life in ATTR-CM
News Coverage from ESC 2024: Vutrisiran Reduces Cardiovascular Risk, Improves Quality of Life in ATTR-CM The HELIOS-B trial has returned promising results, indicating use of vutrisiran (Amvuttra), a novel RNA interference therapy, could provide significant benefit on both outcomes and quality of life for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Presented at the European Society of Cardiology […]
Broadcasting from ESC 2024 – ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI
Broadcasting from ESC 2024 – ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI For patients with a history of myocardial infarction, continuing treatment with beta-blockers could be an unnecessary practice, according to the results of the ABYSS trial. Coming less than a year after REDUCE-AMI thrust the issue into the spotlight, the […]
Newly reported from ESC 2024: Smoking Cessation Halves MACE Risk, Reduction Offers Little Protection
Newly reported from ESC 2024: Smoking Cessation Halves MACE Risk, Reduction Offers Little Protection Quitting smoking after a diagnosis of stable coronary artery disease (CAD) was linked to a nearly 50% reduction in the risk of major cardiovascular (CV) events, although cutting down smoking demonstrated little impact on CV risk, according to new research.1 These 5-year follow-up […]
ESC Congress 2024 Lipidology Preview, with Professor Kausik Ray
ESC Congress 2024 Lipidology Preview, with Professor Kausik Ray Boasting 12 Hot Line sessions, 26 late-breaking science sessions, 38 late-breaking trials, and more than 230 other sessions, the European Society of Cardiology (ESC) Congress 2024 has the potential to be 1 of the most influential cardiology meetings in recent memory. With the meeting headlined by anticipated data releases from […]
ESC Congress 2024 Clinical Trials to Watch, with Deepak Bhatt, MD, MPH, MBA
ESC Congress 2024 Clinical Trials to Watch, with Deepak Bhatt, MD, MPH, MBA Although both the American College of Cardiology and American Heart Association annual meetings are held in high esteem and renowned as platforms for sharing the latest clinically impactful and relevant research findings in cardiology, it is their European-based counterpart, the European Society […]
Newly reported from ACC 2024: Olezarsen Shows Ability to Reduce Triglycerides for Patients with FCS in BALANCE Trial
Newly reported from ACC 2024: Olezarsen Shows Ability to Reduce Triglycerides for Patients with FCS in BALANCE Trial A phase 3 trial of olezarsen suggests the APOC3 inhibitor could prove useful in the management of familial chylomicronemia syndrome (FCS). Results of the trial, called the BALANCE study, the olezarsen 80 mg monthly dose met the primary […]
Reporting from ACC 2024: Trends in Targeted Temperature Management Before and After 2013, with José López, MD
Reporting from ACC 2024: Trends in Targeted Temperature Management Before and After 2013, with José López, MD An analysis of data from the National Inpatient Sample over 15 years details the impact of the 2013 publication of the TTM trial on use of targeted temperature management (TTM) in the US. Presented at the American College of […]
